Gelteq (GELS) Competitors

$0.56 -0.04 (-6.67%)

Closing price 03:57 PM Eastern

Extended Trading

$0.54 -0.02 (-3.39%)

As of 06:44 PM Eastern

GELS vs. ABVC, KYNB, TVRD, NNVC, and AYTU

Should you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include ABVC BioPharma (ABVC), Kyntra Bio (KYNB), Tvardi Therapeutics (TVRD), NanoViricides (NNVC), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry.

How does Gelteq compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

: In the previous week, ABVC BioPharma's average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score.
Company Overall Sentiment
ABVC BioPharma Neutral
Gelteq Neutral
: Gelteq has lower revenue, but higher earnings than ABVC BioPharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ABVC BioPharma $510K 51.38 -$7.91M -$0.40 N/A
Gelteq $110K 54.52 -$4.30M N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Gelteq
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: ABVC BioPharma has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Gelteq has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.
: 11.4% of ABVC BioPharma shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Gelteq's return on equity of 0.00% beat ABVC BioPharma's return on equity.
Company Net Margins Return on Equity Return on Assets
ABVC BioPharma N/A -65.11% -40.13%
Gelteq N/A N/A N/A

Company	Overall Sentiment
ABVC BioPharma	Neutral
Gelteq	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	51.38	-$7.91M	-$0.40	N/A
Gelteq	$110K	54.52	-$4.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-65.11%	-40.13%
Gelteq	N/A	N/A	N/A

Summary

ABVC BioPharma and Gelteq tied by winning 4 of the 8 factors compared between the two stocks.

How does Gelteq compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Gelteq (NASDAQ:GELS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
Gelteq
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Kyntra Bio had 2 more articles in the media than Gelteq. MarketBeat recorded 2 mentions for Kyntra Bio and 0 mentions for Gelteq. Kyntra Bio's average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score.
Company Overall Sentiment
Kyntra Bio Neutral
Gelteq Neutral
: Kyntra Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Gelteq has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
: Kyntra Bio has higher revenue and earnings than Gelteq.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kyntra Bio $6.44M 4.46 $183.45M $45.47 0.16
Gelteq $110K 54.52 -$4.30M N/A N/A
: Kyntra Bio has a net margin of 2,848.19% compared to Gelteq's net margin of 0.00%.
Company Net Margins Return on Equity Return on Assets
Kyntra Bio 2,848.19% N/A -34.39%
Gelteq N/A N/A N/A
: 72.7% of Kyntra Bio shares are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Kyntra Bio	Neutral
Gelteq	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.46	$183.45M	$45.47	0.16
Gelteq	$110K	54.52	-$4.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,848.19%	N/A	-34.39%
Gelteq	N/A	N/A	N/A

Summary

Kyntra Bio beats Gelteq on 9 of the 11 factors compared between the two stocks.

How does Gelteq compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

: Tvardi Therapeutics currently has a consensus target price of $55.50, suggesting a potential upside of 1,404.07%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Gelteq.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tvardi Therapeutics
1 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.50
Gelteq
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Tvardi Therapeutics' average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score.
Company Overall Sentiment
Tvardi Therapeutics Neutral
Gelteq Neutral
: Tvardi Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Gelteq has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
: Gelteq has lower revenue, but higher earnings than Tvardi Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tvardi Therapeutics $7.14M 4.85 -$18.21M -$5.59 N/A
Gelteq $110K 54.52 -$4.30M N/A N/A
: Gelteq's return on equity of 0.00% beat Tvardi Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Tvardi Therapeutics N/A -73.53% -35.22%
Gelteq N/A N/A N/A
: 44.7% of Tvardi Therapeutics shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Tvardi Therapeutics	Neutral
Gelteq	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	4.85	-$18.21M	-$5.59	N/A
Gelteq	$110K	54.52	-$4.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-73.53%	-35.22%
Gelteq	N/A	N/A	N/A

Summary

Tvardi Therapeutics beats Gelteq on 8 of the 12 factors compared between the two stocks.

How does Gelteq compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

: In the previous week, NanoViricides had 4 more articles in the media than Gelteq. MarketBeat recorded 4 mentions for NanoViricides and 0 mentions for Gelteq. NanoViricides' average media sentiment score of 0.39 beat Gelteq's score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.
Company Overall Sentiment
NanoViricides Neutral
Gelteq Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NanoViricides
0 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
Gelteq
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Gelteq's return on equity of 0.00% beat NanoViricides' return on equity.
Company Net Margins Return on Equity Return on Assets
NanoViricides N/A -87.90% -78.69%
Gelteq N/A N/A N/A
: NanoViricides has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Gelteq has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
: Gelteq has higher revenue and earnings than NanoViricides.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NanoViricides N/A N/A -$8.29M -$0.48 N/A
Gelteq $110K 54.52 -$4.30M N/A N/A
: 10.3% of NanoViricides shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Overall Sentiment
NanoViricides	Neutral
Gelteq	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Gelteq	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.48	N/A
Gelteq	$110K	54.52	-$4.30M	N/A	N/A

Summary

NanoViricides beats Gelteq on 7 of the 11 factors compared between the two stocks.

How does Gelteq compare to Aytu BioPharma?

Gelteq (NASDAQ:GELS) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

: In the previous week, Aytu BioPharma had 2 more articles in the media than Gelteq. MarketBeat recorded 2 mentions for Aytu BioPharma and 0 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.
Company Overall Sentiment
Gelteq Neutral
Aytu BioPharma Neutral
: Aytu BioPharma has a consensus target price of $9.33, indicating a potential upside of 263.16%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Gelteq.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gelteq
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Aytu BioPharma
2 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.20
: Gelteq has a net margin of 0.00% compared to Aytu BioPharma's net margin of -39.02%. Gelteq's return on equity of 0.00% beat Aytu BioPharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Gelteq N/A N/A N/A
Aytu BioPharma -39.02% -28.22% -5.20%
: Gelteq has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.
: Gelteq has higher earnings, but lower revenue than Aytu BioPharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gelteq $110K 54.52 -$4.30M N/A N/A
Aytu BioPharma $66.38M 0.42 -$13.56M -$3.84 N/A
: 33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Overall Sentiment
Gelteq	Neutral
Aytu BioPharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Aytu BioPharma	-39.02%	-28.22%	-5.20%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	54.52	-$4.30M	N/A	N/A
Aytu BioPharma	$66.38M	0.42	-$13.56M	-$3.84	N/A

Summary

Aytu BioPharma beats Gelteq on 8 of the 13 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.43M	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	N/A	22.62	24.91	23.23
Price / Sales	54.52	280.78	504.56	75.49
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	0.52	7.05	9.67	6.69
Net Income	-$4.30M	$23.62M	$3.55B	$332.64M
7 Day Performance	-15.79%	3.67%	1.70%	2.01%
1 Month Performance	-17.53%	7.17%	5.62%	9.19%
1 Year Performance	-66.47%	67.04%	34.42%	39.59%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	N/A	$0.56 -6.7%	N/A	N/A	$6.43M	$110K	N/A	N/A	Gap Up High Trading Volume
ABVC ABVC BioPharma	0.2334 of 5 stars	$1.07 -6.1%	N/A	N/A	$29M	$510K	N/A	30
KYNB Kyntra Bio	0.9308 of 5 stars	$7.14 +1.9%	N/A	N/A	$28.37M	$6.44M	0.16	570	News Coverage
TVRD Tvardi Therapeutics	1.6246 of 5 stars	$3.10 +3.0%	$55.50 +1,690.3%	N/A	$28.24M	$7.14M	N/A	80
NNVC NanoViricides	0.4653 of 5 stars	$1.26 -3.1%	N/A	N/A	$28.07M	N/A	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. ABVC, KYNB, TVRD, NNVC, and AYTU

How does Gelteq compare to ABVC BioPharma?

Summary

How does Gelteq compare to Kyntra Bio?

Summary

How does Gelteq compare to Tvardi Therapeutics?

Summary

How does Gelteq compare to NanoViricides?

Summary

How does Gelteq compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. ABVC, KYNB, TVRD, NNVC, and AYTU

How does Gelteq compare to ABVC BioPharma?

Summary

How does Gelteq compare to Kyntra Bio?

Summary

How does Gelteq compare to Tvardi Therapeutics?

Summary

How does Gelteq compare to NanoViricides?

Summary

How does Gelteq compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools